New data show precision cancer testing still lags for Black, Hispanic, low-income and Medicare/Medicaid patients, delaying ...
HER2-targeted ADCs show ~50% response rates in pretreated endometrial cancer, with durable responses and manageable safety ...
In the intent-to-treat population, the median OS was 13.2 months with daraxonrasib vs 6.7 months for chemotherapy, ...
Pancreatic cancer research tackles treatment resistance with targeted drug delivery, immune-boosting combinations, and ...
In this segment on advanced renal cell carcinoma, Dr. Geynisman raises the increasingly relevant question of how prior ...
In this segment on advanced renal cell carcinoma, Dr. McGregor focuses on how clinicians move beyond guideline ...
Lilit Karapetyan of the Moffitt Cancer Center details a significant shift in clinical confidence regarding the treatment of ...
AZD0120, a rapidly manufactured CAR T product, was used successfully in a small number of patients with multiple myeloma with ...
O'Cearbhaill, MD, of Memorial Sloan Kettering Cancer Center discussed the rationale and early progress of a phase 1/2 ...
SCLC, addressing a high-relapse setting with limited second-line efficacy and modest survival benefit. Ifinatamab deruxtecan ...
Nodal burden predicts higher preoperative ctHPVDNA levels, while aggressive pathologic features paradoxically correlate with ...
FDA acceptance positions 18F-FET as a potential first-in-class US-approved amino acid PET agent for glioma characterization, addressing a major posttreatment imaging specificity gap.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results